Protein kinases are critical drug targets against cancer. Since the discovery of Gleevec, a
specific inhibitor of Abl kinase, the capability of this drug to distinguish between Abl and …

Tyrosine kinases present attractive drug targets for specific types of cancers. Gleevec, a well-
known therapeutic agent against chronic myelogenous leukemia, is an effective inhibitor of …

Gleevec is a potent inhibitor of Abl tyrosine kinase but not of the highly homologous c-Src
kinase. Because the ligand binds to an inactive form of the protein in which an Asp-Phe-Gly …

Protein kinases are obvious drug targets against cancer, owing to their central role in
cellular regulation. Since the discovery of Gleevec, a potent and specific inhibitor of Abl …

Gleevec, a well-known cancer therapeutic agent, is an effective inhibitor of several tyrosine
kinases, including Abl and c-Kit, but displays less potency to inhibit closely homologous …

Macromolecular function is rooted in energy landscapes, where sequence determines not a
single structure but an ensemble of conformations. Hence, evolution modifies a protein's …

In this work, we have examined the molecular mechanisms of allosteric regulation of the
ABL tyrosine kinase at the atomic level. Atomistic modeling of the ABL complexes with a …

Understanding protein conformational variability remains a challenge in drug discovery. The
issue arises in protein kinases, whose multiple conformational states can affect the binding …

Quantifying binding specificity and drug resistance of protein kinase inhibitors is of
fundamental importance and remains highly challenging due to complex interplay of …

Abelson kinase (c-Abl) is a non-receptor tyrosine kinase involved in several biological
processes essential for cell differentiation, migration, proliferation, and survival. This …